Bioconnect CE marks Optiflow anastomotic system
This article was originally published in Clinica
Executive Summary
Bioconnect Systems has CE marked its Optiflow vascular anastomotic system for sale in Europe. The device is intended to create arteriovenous fistulae for vascular access in patients on haemodialysis, such as those with end-stage renal disease. Optiflow improves surgeons' ability to create precise vascular connections, Ambler, Pennsylvania-based Bioconnect claims. The firm believes there is an unmet need for therapies that improve fistula function, as around 60% of access sites fail within the four to five months, according to a study by the US National Institutes of Health.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.